Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214963 | 1.00 | HRH4 (0.34) | HRH4KITMAPK13MAPK12MAPK11 | |
| SCHEMBL12435066 | 0.78 | SMO (0.40) | KITMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1140801 | 0.78 | HRH4 (0.40) | HRH4KITMAPK13MAPK12MAPK11 | |
| SCHEMBL1140803 | 0.78 | HRH4 (0.40) | HRH4KITMAPK13MAPK12MAPK11 | |
| SCHEMBL2895112 | 0.75 | MAPT (0.42) | HRH4KITMAPK13MAPK12MAPK11 | |
| SCHEMBL2897789 | 0.75 | MAPT (0.42) | HRH4KITMAPK13MAPK12MAPK11 | |
| SCHEMBL2214340 | 0.71 | CSNK1E (0.47) | KITMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2214332 | 0.71 | CSNK1E (0.47) | KITMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2216258 | 0.69 | SMO (0.51) | KITMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1828652 | 0.69 | SMO (0.51) | KITMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358703-B1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8445493-B2 | Tetrasubstituted pyridazines hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178093-A1 | TETRASUBSTITUTED PYRIDAZINES HEDGEHOG PATHWAY ANTAGONISTS | SMO, SHH, GLI1 | HRH4 84/4885KIT 570/4885MAPK13 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.